Also, adoptive T cell therapies targeting MelanA/MART-1, gp100, and NY-ESO-1 have induced objective clinical responses in melanoma and other cancers, supporting these as cancer-rejection antigens32–34. This evidence concerns the gene PMEL and cancer.